<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016714</url>
  </required_header>
  <id_info>
    <org_study_id>V114-026</org_study_id>
    <secondary_id>2018-003788-70</secondary_id>
    <secondary_id>V114-026</secondary_id>
    <nct_id>NCT04016714</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)</brief_title>
  <acronym>PNEU-PED-EU-2</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and immunogenicity of a 3-dose
      schedule (2-dose primary series followed by a toddler dose) of pneumococcal conjugate vaccine
      (PCV) as one of the currently recommended by the World Health Organization (WHO) Strategic
      Advisory Group of Experts (SAGE) on Immunizations and practiced in many countries.

      The primary hypotheses are that V114 is non-inferior to Prevnar 13® for the 13 shared
      serotypes based on response rates and on anti-pneumococcal polysaccharide (PnPs)
      serotype-specific Immunoglobulin G (IgG) geometric mean concentrations (GMCs) at 30 days
      following Dose 3; that V114 is superior to Prevnar 13® for the 2 serotypes unique to V114
      based on the response rates and on anti-PnPs serotype-specific IgG GMCs at 30 days following
      Dose 3; and that Vaxelis™ administered concomitantly with V114 is non-inferior to Vaxelis™
      administered concomitantly with Prevnar 13® at 30 days following Dose 3 for each antigen
      included in Vaxelis™.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 28, 2019</start_date>
  <completion_date type="Anticipated">November 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Injection-Site Adverse Event</measure>
    <time_frame>Day 1 to Day 14 post any vaccination</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be swelling, redness, pain or tenderness, and hard lump.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Day 1 to Day 14 post any vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be irritability, drowsiness, appetite loss, and hives or welts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Vaccine-Related Serious Adverse Event</measure>
    <time_frame>Up to 6 months after Dose 3 (up to 194 days)</time_frame>
    <description>An SAE is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Meeting the Serotype Specific Immunoglobulin G (IgG) Threshold Value of ≥0.35 μg/mL for Each Serotype in V114</measure>
    <time_frame>30 days after Dose 3</time_frame>
    <description>Assess the anti-pneumococcal polysaccharide (PnPs) serotype-specific IgG response rates (percentage of participants meeting serotype-specific IgG threshold value of ≥0.35 μg/mL) for the 15 serotypes contained in V114 as measured by the pneumococcal electrochemiluminescence (Pn ECL) assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Serotype-Specific IgG for Each Serotype in V114</measure>
    <time_frame>30 days after Dose 3</time_frame>
    <description>Assess the anti-PnPs serotype-specific IgG GMCs for the 15 serotypes contained in V114 as measured by the Pn ECL assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Antigen-Specific Antibody Threshold Value for each Antigen Included in Vaxelis™</measure>
    <time_frame>30 days after Dose 3</time_frame>
    <description>Assess the antibody responses to each antigen in Vaxelis™: diphtheria toxoid, tetanus toxoid, pertussis toxin (PT), pertussis filamentous hemagglutinin (FHA), pertussis fimbriae 2/3 (FIM 2/3), pertussis pertactin (PRN), Haemophilus influenzae type b polyribosylribitol phosphate (Hib-PRP), hepatitis B surface antigen (HBsAg), and poliovirus serotypes 1, 2, and 3. The percentage of participants administered V114 concomitantly with Vaxelis™ versus participants administered with Prevnar 13™ concomitantly with Vaxelis™ will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Serotype Specific IgG Threshold Value of ≥0.35 μg/mL for each Serotype in V114</measure>
    <time_frame>30 days after Dose 2</time_frame>
    <description>Assess the anti-PnP serotype-specific IgG responses for the 15 serotypes contained in V114.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMC of Serotype-Specific IgG for Each Serotype in V114</measure>
    <time_frame>30 days after Dose 2</time_frame>
    <description>Assess the anti-PnPs serotype-specific IgG GMCs for the 15 serotypes contained in V114.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Serotype-Specific Opsonophagocytic Activity (OPA) Threshold Value for Each Serotype in V114</measure>
    <time_frame>30 days after Dose 3</time_frame>
    <description>Assess the anti-PnPs serotype-specific OPA responses for the 15 serotypes contained in V114.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Serotype-Specific OPA for Each Serotype in V114</measure>
    <time_frame>30 days after Dose 3</time_frame>
    <description>Assess the anti-PnPs serotype-specific OPA GMTs for the 15 serotypes contained in V114.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1180</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2 and 4 (approximately 3, 5, and 12 months of age).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infant participants will receive a single 0.5 mL IM injection of Prevnar 13® at Visit 1, 2 and 4 (approximately 3, 5, and 12 months of age).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.</description>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevnar 13®</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.</description>
    <arm_group_label>Prevnar 13®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaxelis™</intervention_name>
    <description>Intramuscular 0.5 mL single dose</description>
    <arm_group_label>Prevnar 13®</arm_group_label>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M-M-R®II</intervention_name>
    <description>Subcutaneous 0.5 mL single dose</description>
    <arm_group_label>Prevnar 13®</arm_group_label>
    <arm_group_label>V114</arm_group_label>
    <other_name>Measles, Mumps, and Rubella Virus Vaccine Live</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varivax®</intervention_name>
    <description>Subcutaneous 0.5 mL single dose</description>
    <arm_group_label>Prevnar 13®</arm_group_label>
    <arm_group_label>V114</arm_group_label>
    <other_name>Varicella Vaccine Live</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is male or female, approximately 3 months of age, from 70 days to 111 days inclusive,
             at the time of signing the informed consent.

          -  Has a legally acceptable representative who understands the study procedures,
             alternate treatments available, and risks involved with the study and voluntarily
             agrees to participate by giving written informed consent.

        Exclusion Criteria:

          -  Was born prior to 37 weeks of gestation.

          -  Has a history of invasive pneumococcal disease (IPD) or known history of other culture
             positive pneumococcal disease.

          -  Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine
             (PCV), any component of the licensed pediatric vaccines to be administered
             concomitantly in the study, or any diphtheria toxoid containing vaccine.

          -  Has any contraindication to the concomitant study vaccines being administered in the
             study.

          -  Has a known or suspected impairment of immunological function.

          -  Has a history of congenital or acquired immunodeficiency.

          -  Has, or his/her mother has, a documented human immunodeficiency virus (HIV) infection.

          -  Has, or his/her mother has, a documented hepatitis B surface antigen - positive test.

          -  Has known or history of functional or anatomic asplenia.

          -  Has failure to thrive based on the clinical judgement of the investigator.

          -  Has a bleeding disorder contraindicating intramuscular vaccination.

          -  Has a history of autoimmune disease (including but not limited to systemic lupus
             erythematosus, antiphospholipid syndrome, Behcet's disease, autoimmune thyroid
             disease, polymyositis and dermatomyositis, scleroderma, type 1 diabetes mellitus, or
             other autoimmune disorders).

          -  Has a known neurologic or cognitive behavioral disorder, including
             encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development
             disorder, and related disorders.

          -  Has received a dose of any pneumococcal vaccine prior to study entry.

          -  Has received &gt;1 dose of monovalent hepatitis B vaccine or hepatitis B-based
             combination vaccine prior to study entry.

          -  Has received a dose of any acellular pertussis- or whole cell pertussis-based
             combination vaccines, Haemophilus influenza type b conjugate vaccine, poliovirus
             vaccine, or any other combination thereof, prior to study entry.

          -  Has received a blood transfusion or blood products, including immunoglobulins.

          -  Has participated in another clinical study of an investigational product before the
             beginning or anytime during the duration of the current clinical study. Participants
             enrolled in observational studies may be included; these will be reviewed on a case
             by-case basis for approval by the Sponsor.

          -  Has any other reason that, in the opinion of the investigator, may interfere with the
             evaluation required by the study. Reasons may include, but are not limited to, being
             unable to keep appointments or planning to relocate during the study.

          -  Is or has an immediate family member (e.g., parent/legal guardian or sibling) who is
             investigational site or Sponsor staff directly involved with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Days</minimum_age>
    <maximum_age>111 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre Hospital ( Site 0003)</name>
      <address>
        <city>Hvidovre</city>
        <state>Hovedstaden</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshosp. Skejby ( Site 0002)</name>
      <address>
        <city>Aarhus</city>
        <state>Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Herning Hospitalsenheden Vest ( Site 0006)</name>
      <address>
        <city>Herning</city>
        <state>Midtjylland</state>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitetshospital ( Site 0005)</name>
      <address>
        <city>Aalborg</city>
        <state>Nordjylland</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sygehus Vendsyssel Hjoerring ( Site 0004)</name>
      <address>
        <city>Hjoerring</city>
        <state>Nordjylland</state>
        <zip>9800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital ( Site 0001)</name>
      <address>
        <city>Odense C</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokkolan rokotetutkimusklinikka ( Site 0029)</name>
      <address>
        <city>Kokkola</city>
        <state>Mellersta Osterbotten</state>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto - Tampereen rokotetutkimusklinikka ( Site 0021)</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Oulun rokotetutkimusklinikka ( Site 0030)</name>
      <address>
        <city>Oulu</city>
        <state>Pohjois-Pohjanmaa</state>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porin rokotetutkimusklinikka ( Site 0027)</name>
      <address>
        <city>Pori</city>
        <state>Satakunta</state>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinajoki Vaccine Research Center ( Site 0028)</name>
      <address>
        <city>Seinajoki</city>
        <state>Sodra Osterbotten</state>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Espoon rokotetutkimusklinikka ( Site 0024)</name>
      <address>
        <city>Espoo</city>
        <state>Uusimaa</state>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Etela-Helsingin Rokotetutkimusklinikka ( Site 0022)</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Ita-Helsingin rokotetutkimusklinikka ( Site 0023)</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jarvenpaan rokotetutkimuskeskus ( Site 0025)</name>
      <address>
        <city>Jarvenpaa</city>
        <state>Uusimaa</state>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turun rokotetutkimuskeskus ( Site 0026)</name>
      <address>
        <city>Turku</city>
        <state>Varsinais-Suomi</state>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli ( Site 0048)</name>
      <address>
        <city>Rome</city>
        <state>Roma</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Policlinico Consorziale di Bari ( Site 0044)</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Riuniti Di Foggia - Igiene Universitaria ( Site 0046)</name>
      <address>
        <city>Foggia</city>
        <zip>71121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Policlinico San Martino ( Site 0042)</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger universitetssykehus ( Site 0062)</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset i Vestfold ( Site 0063)</name>
      <address>
        <city>Toensberg</city>
        <state>Vestfold</state>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF Ulleval Sykehus ( Site 0061)</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus ( Site 0100)</name>
      <address>
        <city>Umea</city>
        <state>Vasterbottens Lan [se-24]</state>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

